发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
PURPOSE:Systemic immune-inflammation index (SII) has been demonstrated to be closely associated with prognosis of a series of solid tumors. However, its role in small cell lung cancer (SCLC) remains poorly understood. The present study aims to evaluate the prognostic significance of pretreatment SII in SCLC treated with etoposide and platinum-based chemotherapy. METHODS:Sixty hundred and fifty-three newly diagnosed SCLC patients were enrolled. The optimal cut-off values for SII and LDH (lactate dehydrogenase) were obtained by a receiver operating characteristic (ROC) curve analysis. Overall survival (OS) was assessed by univariate and multivariate analyses. RESULTS:The optimal cut-off values of pretreatment SII and LDH were 748.51 × 109/L and 188.5 U/L, respectively. High pretreatment SII was significantly associated with advanced tumor stage (limited disease, LD vs. extensive disease, ED; 26.3% vs 46.5%; p < 0.001). On univariate analysis, age < 65 years, female, non-smoker, limited disease, SII < 748.51 × 109/L, LDH < 188.5 U/L, distant metastasis numbers < 2, chemotherapy + radiotherapy, and chemotherapy + surgery were closely correlated with a prolonged OS (p < 0.05). The median OS for patients in high SII group was 12.0 months, compared with that of 17.0 months for patients in low SII group. Multivariate analysis showed smoking history (p = 0.014), tumor stage (p < 0.001), pretreatment SII (p < 0.001), LDH (p = 0.002), distant metastasis numbers (p = 0.006), and chemotherapy + radiotherapy (p < 0.001) were independent prognostic factors of OS. Furthermore, SII remained prognostic significance for SCLC stratified by variable subgroups analysis. CONCLUSION:Pretreatment SII represents a powerful prognostic biomarker for SCLC patients treated with etoposide and platinum-based chemotherapy. It is significant for treatment strategy making in clinics.
展开更多
最新影响因子:3.777 | 期刊ISSN:0341-2040 | CiteScore:1.85 |
出版周期:Bimonthly | 是否OA:YES | 出版年份:1976 |
自引率:3.00% | 研究方向:医学-呼吸系统 |
出版地区:GERMANY |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
Lung publishes original articles reviews and editorials on all aspects of the healthy and diseased lungs of the airways and of breathing. Epidemiological clinical pathophysiological biochemical and pharmacological studies fall within the scope of the journal. Case reports short communications and technical notes can be accepted if they are of particular interest. The journal does not impose page charges.
Lung发表了关于气道健康和患病肺部以及呼吸各方面的原创文章评论和社论。流行病学、临床病理生理学、生物化学和药理学研究属于本杂志的范围。如果对案件报告特别感兴趣,可以接受简短的沟通和技术说明。该杂志不收取书页费用。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
RESPIRATORY SYSTEM (呼吸系统) 4区 |
41/60 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
102 | 95 | 7 |
引文计数(2018)
文献(2015-2017)
796次引用
430篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Pulmonary and Respiratory Medicine
|
#52/132
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
liting7111
研究方向:呼吸基础 呼吸临床
审稿时间: 3个月内 接受率: 中等(50%命中)
liting7111
审稿时间: 6个月内
影响因子:1.714
ISSN:1386-2073
研究方向:化学-生化研究方法
影响因子:6.088
ISSN:1933-7213
研究方向:医学-神经科学
影响因子:1.379
ISSN:0362-5664
研究方向:医学-临床神经学
影响因子:4.287
ISSN:1473-7175
研究方向:CLINICAL NEUROLOGY-PHARMACOLOGY & PHARMACY
影响因子:1.821
ISSN:1528-4336
研究方向:医学-传染病学
影响因子:2.385
ISSN:1120-009X
研究方向:医学-药学
影响因子:2.706
ISSN:1076-6294
研究方向:医学-传染病学
影响因子:4.177
ISSN:1178-6973
研究方向:-
影响因子:5.758
ISSN:0305-7453
研究方向:医学-传染病学
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
LUNG 投稿经验
(由下方点评分析获得,3人参与,16059人阅读)